Probiotics for Immune Support
Live microorganisms, commonly Lactobacillus and Bifidobacterium strains, that colonise the gut and influence digestion and immune signalling via short-chain fatty acid production; effects are strain- and dose-specific.
Probiotics for Immune Support
3 of 3 results reported a benefit, from 1 published study.
1 randomised trial · the chart counts everything measured
- 3 reported a benefit
Colour keyReported a benefitNo clear benefitUnclearPossible harmAmber is for highlights, such as where the most research is. It never means a result was good.
3 laboratory markers also measured
- Gut immune signalling proteins · lab markerReported a benefitmeasurement not reportedTh2 and Th17 cytokines were silenced in breastfed infants given Bifidobacterium infantis EVC001 compared to those lacking bifidobacteria.1 randomised trial2021 study ↗
- Immune-regulating protein (galectin-1) · lab markerReported a benefitmeasurement not reportedGalectin-1 was upregulated in Th2 and Th17 cells in infants supplemented with Bifidobacterium infantis EVC001 compared to those lacking bifidobacteria.1 randomised trial2021 study ↗
- Interferon beta levels · lab markerReported a benefitmeasurement not reportedInterferon beta was induced in breastfed infants given Bifidobacterium infantis EVC001 compared to those lacking bifidobacteria.1 randomised trial2021 study ↗
These are the figures the studies reported, not a prediction for any one person. Where several studies measured the same thing in the same unit, we show a simple average and say so. Every result is listed below.
See every resultThe connection
Frequent illness, weak immune response, slow recovery from infections.
Also known as: Lactobacillus, Bifidobacterium, Saccharomyces boulardii
Probiotics × Immune Support: at a glance
Every published result for this pair, extracted and audited.
These charts count reported findings from published studies, grouped by reported benefit and study design. Study design is not a certainty grade.
Probiotics / Immune Support: reported findings; one study may contribute several findings.
What the evidence shows
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Benefit | 3 |
Study designs behind these findings
What this means: Counts describe research quantity, not treatment effectiveness or certainty.
| Category | Findings (count) |
|---|---|
| Randomised trial | 3 |
- Studies
- 1
| Study | Outcome | Reported result | Uncertainty (as reported) | Study duration |
|---|---|---|---|---|
| Bifidobacteria-mediated immune system imprinting early in life. (PMID 34143954) | immunoregulatory galectin-1 | Not reported | Not reported | first months of life |
| Bifidobacteria-mediated immune system imprinting early in life. (PMID 34143954) | interferon beta (IFN-beta) | Not reported | Not reported | first months of life |
| Bifidobacteria-mediated immune system imprinting early in life. (PMID 34143954) | intestinal T helper 2 (Th2) and Th17 cytokines | Not reported | Not reported | first months of life |
Study results, as reported by the publications
Every measured outcome, one row per finding - numbers exactly as reported. Units are preserved where supplied; missing units are not inferred.
| Study and type | Reported sample and duration | Outcome measured | Reported result | What studies found |
|---|---|---|---|---|
| PMID 34143954 2021 Randomised trial | Sample (as reported): Not reportedDuration: first months of life | immunoregulatory galectin-1 | Not reported | Benefit |
| PMID 34143954 2021 Randomised trial | Sample (as reported): Not reportedDuration: first months of life | interferon beta (IFN-beta) | Not reported | Benefit |
| PMID 34143954 2021 Randomised trial | Sample (as reported): Not reportedDuration: first months of life | intestinal T helper 2 (Th2) and Th17 cytokines | Not reported | Benefit |
Probiotics × Immune Support: the evidence base
Hand-selected PubMed studies, linked to the originals.
Ordered by strength of evidence, then result direction.
01Comparison of adjuvant and neoadjuvant therapies for muscle invasive bladder cancer: A network meta-analysisPetrelli F, et al. · Urologic oncology · 2026PMID 40935764 ↗02Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026Weiss SL, et al. · Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies · 2026PMID 41869844 ↗03Surviving Sepsis Campaign International Guidelines for the Management of Sepsis and Septic Shock in Children 2026Weiss SL, et al. · Intensive care medicine · 2026PMID 41870559 ↗04Effect of nutritional interventions on the psychological symptoms of premenstrual syndrome in women of reproductive age: a systematic review of randomized controlled trialsRobinson J, et al. · Nutrition reviews · 2025PMID 38684926 ↗05Vitamin D's Impact on Cancer Incidence and Mortality: A Systematic ReviewWimalawansa SJ · Nutrients · 2025PMID 40732958 ↗06Therapeutic effects of high-dose vitamin C supplementation in patients with COVID-19: a meta-analysisSun L, et al. · Nutrition reviews · 2024PMID 37682265 ↗Community experiences
Contributors volunteered; this does not establish treatment effectiveness or population incidence.
Reported changes
No publishable community breakdown is available. This does not establish that no reports exist.